Recombinant Virus Vaccines
Document text
Principal Investigator: Bernard Moss Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Fiscal Year: 2024 Award: $1,617,431 Funding agency: National Institute of Allergy and Infectious Diseases During F7'24 progress has been made in developing improved vaccines for mpox and infections caused by other orthopoxviruses. We have continued our collaboration with the company Moderna using mRNAs expressing four modified mpox virus proteins encapsulated in a lipid particle. During the past year, the research has expanded to evaluate protection against mucosal and cutaneous infections and the role of antibody. In addition, we are continuing studies on mpox protein nanoparticles as orthopoxvirus vaccines. In other studies we have evaluated immune responses to the licensed Jynneos vaccine. Terms: <Animal Model><Animal Models and Related Studies><Antibodies><Cell Mediated Immunology><Cell-Mediated Immunity><Cellular Immunity><Collaborations><Disease><Disorder><Encapsulated><Immune response><Immunological response><Infection><Infectious Skin Diseases><Licensing><Lipids><Messenger RNA><Monkey Pox><Monkey Pox Virus><Monkeypox><Monkeypox virus><Monkeypoxvirus><Mucosa><Mucosal Tissue><Mucous Membrane><Orthopox virus><Orthopoxvirus><Proteins><RNA vaccine><RNA-based vaccine><Recombinant Proteins><Recombinant Viral Vaccine><Research><Role><Testing><Vaccines><Viral Antigens><Viral Gene Products><Viral Gene Proteins><Viral Proteins><cutaneous infection><host response><immune system response><immunoresponse><improved><infected skin><mRNA><mRNA vaccine><mRNA-based vaccine><model of animal><mpox><mpox virus><mpxv><nano particle><nano-sized particle><nanoparticle><nanosized particle><particle><recombinant virus vaccine><side effect><skin infection><social role><vaccine candidate><vector><virus antigen><virus protein>